Skip to main content

Table 3 Comparison of baseline characteristics between successful long-term maintenance group (n = 6) vs. Secondary failure group (n = 4)

From: Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

 Secondary failure
(n = 4)
Patients with successful long-term maintenance
(n = 6)
p-value
Age, mean (SD), years60.75 ± 6.741.8 ± 15.23< 0.05
Female, n (%)2 (50%)4 (66.7%)NS
Disease duration, mean (SD), years15 ± 14.077.8 ± 4.35NS
TCZ exposure before tapering, months (SD)19.5 ± 7.2314.8 ± 7.5NS
Remission achievement delay, months (SD)3.5 ± 3.42.16 ± 2.4NS
Remission duration, months (SD)8 ± 5.74.8 ± 2.13NS
RF positive, n (%)3 (75%)2 (33.3%)NS
ACPA positive, n (%)3 (75%)2 (33.3%)NS
Erosive status, n (%)4 (100%)4 (66.7%)NS
Previous number of sDMARDs2.75 ± 1.252 ± 0.63NS
Previous number of bDMARDs1.5 ± 1.731.66 ± 1.21NS
Swollen joint count00.166 ± 0.4NS
Tender joint count2.25 ± 2.63.16 ± 4.57NS
Hyperhemia at Doppler1 (25%)1 (16.7%)NS
Number of patients with active synovitis1 (25%)4 (66.7%)NS
Number of active synovitis
 Hands84NS
 Feet05NS
Concomitant therapy
 MTX, n (%)2(50%)2(33.3%)NS
 LEF, n (%)0(0%)2 (33.3%)NS
DAS28; mean (SD)1.48 ± 1.11.51 ± 1.05NS
ESR, mm/h; mean (SD)7.5 ± 116.66 ± 10.1NS
CRP, mg/L, mean (SD)2.55 ± 3.33 ± 1.87NS
TCZ plasma level, mg/L; mean (SD)7.12 ± 7.77.35 ± 6.41NS
ADAb positivity00NS
Flare, mean (SD)2 ± 01 ± 0.90.07
  1. SD standard deviation, n number, TCZ tocilizumab, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, MTX methotrexate, LEF leflunomide, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ADAb antidrug antibodies, NS non significant